Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pseudoxanthoma elasticum: an update.

D W Sherer1, A N Sapadin, M G Lebwohl

  • 1Mount Sinai School of Medicine, New York, NY 10029-6574, USA.

Dermatology (Basel, Switzerland)
|August 18, 1999
PubMed
Summary

Pseudoxanthoma elasticum (PXE) is a rare genetic disorder affecting elastic tissue, often underdiagnosed. This update covers PXE presentations, genetics, childhood concerns, and management strategies for better patient care.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.

The British journal of dermatology·2021
Same author

Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same author

Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019

Area of Science:

  • Medical Genetics
  • Dermatology
  • Ophthalmology

Background:

  • Pseudoxanthoma elasticum (PXE) is an inherited connective tissue disorder affecting elastic fibers.
  • PXE presents with diverse systemic manifestations, including skin, eye, and cardiovascular issues.
  • Underdiagnosis is common due to physician unfamiliarity and variable disease expression.

Purpose of the Study:

  • To provide a comprehensive update on Pseudoxanthoma elasticum (PXE).
  • To review current knowledge on PXE's clinical presentations, genetics, and management.
  • To highlight the importance of early diagnosis and genetic counseling for PXE patients.

Main Methods:

  • Literature review of recent advancements in PXE research.
  • Synthesis of clinical findings, histopathology, and genetic data.
  • Discussion of management strategies and ongoing research areas.

Main Results:

  • PXE exhibits significant variability in clinical presentation and inheritance patterns.
  • Histopathological findings include calcification and fragmentation of elastic fibers.
  • Early diagnosis and genetic counseling are crucial for managing PXE and its complications.

Conclusions:

  • An updated understanding of PXE is essential for improving diagnosis and patient outcomes.
  • Multidisciplinary management is key for addressing the systemic manifestations of PXE.
  • Continued research is vital for developing novel therapeutic approaches for PXE.

Related Experiment Videos